



The right patient
The right drug
The right time
The right dose
The right route

Precision Medication Dosing (clinically validated)

FOUNDED: 2022

LOCATION: Estonia

STAGE: PreSeed/Seed

INDUSTRY: Personal Medicine; SaaS, PaaS

FUNDING TO DATE: ~ €3,5M (*public sector basic science grants totally, last 10 years*)

TEAM MEMBERS: 5

CHAIR of the BOARD and CSO - Chief Scientific Officer, Partner, Founder - prof **Irja Lutsar**

MEMBER of the BOARD and CTMO – Chief Technology & Medical Officer, Partner, Founder - prof **Tuuli Metsvaht**

MEMBER of the BOARD, CEO&CFO, Founder, Partner - **Margus Maidla**

Senior Infrastructure and Full Stack Engineer - **Raivo Metsvaht**

Senior Statistics and Back-End Engineer - **Hiie Soeorg**, PhD

INVESTMENT OPPORTUNITY: €150,000 - 300,000

USE OF PROCEEDS: Develop a commercial prototype IU for 4-5 different medications and from them one (vancomycin) clinically validated readiness

CONTACT US:

<https://right5.eu/en/>

<https://right5.eu/en/contact/>

+372 5662 0129

INVESTMENT ROUND

SUMMARY: We will launch the clinically validated precision drug dosing software platform, which will help doctors and patients provide personalized dosing of drugs with innovative modern algorithms.

PROBLEM: Many drugs have a narrow therapeutic window, which means that there is very little difference between the dose that produces positive effects on the dose that is toxic. Underdosing, in turn, is often associated with insufficient effect, i.e., that too low a dose of drug does not achieve the desired therapeutic result. Studies have shown that people differ from each other and that the concentrations of medicines vary from person to person after the same dose.

SOLUTION: The Right5 team has developed special software to help people dispense medicines, based on their own personal markers. We believe, that this is the overall future of the full sector. A population-based approach of “one tablet, three times a day” is becoming a thing of the past. New knowledge about the effects of active substances opens up new pharmacokinetic possibilities for drug treatment.

We have explored the effect of different a priori inputs (existing pharmacokinetic models) on the predictive power of dose optimization software. We have tested various published neonatal vancomycin pharmacokinetic models *in silico* and have shown that the choice of input model significantly affects the accuracy of software based dose optimization.

ACCOMPLISHED: Technology is developed in cooperation with universities in last 10 years. Mainly in University of Tartu with lead of Principal Investigators of Right5 founders prof Irja Lutsar and prof Tuuli Metsvaht.

[List and references to the ten most important works of research.](#)

The company owns and further develops unique intellectual property, which gives a market advantage for further development. The IP created in the Seed phase will belong to the company.

MARKET SIZE: The global therapeutic drug monitoring market is projected to reach USD 2.0 billion by 2025 from USD 1.4 billion in 2020, at a CAGR of 6.9% from 2020 to 2025¹

COMPETITORS: There are no competitors operating on a commercial basis with a European capital background. The three main competitors with a US background are:



COMPETITIVE ADVANTAGES:

- Clinically inside IP validated vancomycin - available on DoseMe and Insight RX.
- In the next phase, in addition to increasing the drug portfolio, the possibility of a pharmacogenetic query is added as a service
- Responsive smart device support available to only a few competitors
- Development advantage - subsequent clinical validation of the portfolio with other drugs (such as immediate vancomycin) is about 10 times cheaper than in other developed countries, ie the cost-effectiveness of our development is truly noticeable, not marginal.

BUSINESS MODEL: A public service pharmaceutical software platform for use in hospitals and in the future for the treatment of the chronically ill at home. Can be used with both monthly and annual licenses, as well as one-time payment links.

PRESENTATION: An Investor Deck and a wider presentation are available upon request.

INVESTMENT PURPOSE: Fully functional validated drug dosing platform, machine learning and software improvement, preparation of the further development phase, IP costs, marketing costs (minimum) and preparation of the next investment round. Several applications for public funding are submitted and planned (Enterprise Estonia, European Horisont, etc.), investments will be used for self-financing as a component.

INVESTMENT ROUND TERMS:

Investment round period: Round closed & signed Q3, 2022.

Investment round amount: EUR 50,000 - 100,000

Investment round method: round is divided into investment tickets. One ticket – EUR 25,000

Equity offered: 3% - 5% of total shares + 20% discount at the next investment round.

Investment deadline: After the investment decision is followed by the signing an investment agreement and other legal acts.

¹ <https://www.marketsandmarkets.com/Market-Reports/therapeutic-drug-monitoring-market-155350443.html>